IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
Nadine Bley,Annekatrin Schott,Simon Müller,Danny Misiak,Marcell Lederer,Tommy Fuchs,Chris Alexander Aßmann,Markus Glaß,Christian Ihling,Andrea Sinz,Nikolaos Pazaitis,Claudia Wickenhauser,Martina Vetter,O Ungurs,Hans-Georg Strauss,Christoph Thomssen,Stefan Hüttelmaier +16 more
TLDR
It is shown that the IGF2 mRNA-binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HGSOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism, which reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signalling in ovarian cancer cells.Abstract:
Epithelial-to-mesenchymal transition (EMT) is a hallmark of aggressive, mesenchymal-like high-grade serous ovarian carcinoma (HGSOC). The SRC kinase is a key driver of cancer-associated EMT promoting adherens junction (AJ) disassembly by phosphorylation-driven internalization and degradation of AJ proteins. Here, we show that the IGF2 mRNA-binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HGSOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism. IGF2BP1-driven invasive growth of ovarian cancer cells essentially relies on the SRC-dependent disassembly of AJs. Concomitantly, IGF2BP1 enhances ERK2 expression in an RNA-binding dependent manner. Together this reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signalling in ovarian cancer cells. The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib. However, due to IGF2BP1-directed stimulation, only combinatorial treatment effectively overcomes the IGF2BP1-promoted invasive growth in 3D culture conditions as well as intraperitoneal mouse models. In conclusion, we reveal an unexpected role of IGF2BP1 in enhancing SRC/MAPK-driven invasive growth of ovarian cancer cells. This provides a rationale for the therapeutic benefit of combinatorial SRC/MEK inhibition in mesenchymal-like HGSOC.read more
Citations
More filters
Journal ArticleDOI
RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications
Chang Gu,Xin Shi,Chenyang Dai,Feng Shen,Gaetano Rocco,Jiafei Chen,Zhengyu Huang,Chunji Chen,Chuan He,Tao Huang,Chang Chen +10 more
TL;DR: The underlying mechanisms of m6A modifications in tumorigenesis are emphasized and the potential m 6A regulators-associated therapeutic targets for tumor therapy are introduced.
Journal ArticleDOI
IGF2BP1, a Conserved Regulator of RNA Turnover in Cancer
Markus Glaß,Danny Misiak,Nadine Bley,Simon Müller,Sven Hagemann,Bianca Busch,Alexander Rausch,Stefan Hüttelmaier +7 more
TL;DR: In this paper, the authors present a set of genes and cancer hallmark pathways showing a conserved pattern of deregulation in dependence of IGF2BP1 expression in cancer cell lines, which confirm and expand previous findings on the pivotal role of the oncofetal IGF2 mRNA-binding protein 1 in promoting oncogenic gene expression by stabilizing target mRNAs in a mainly 3'UTR, m6A-, miRNA-, and potentially AU-rich element dependent manner.
Journal ArticleDOI
The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer
TL;DR: The up-to-date knowledges of IGF2BPs (IGF2BP1/2/3) as m6A readers in an m6a-modified manner in cancer progression are reviewed, and the oncogenic role of IGF 2BPs in cancer is discussed.
Journal ArticleDOI
The biological function of IGF2BPs and their role in tumorigenesis.
TL;DR: The insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) pertain to a highly conservative RNA-binding family that works as a post-transcriptional fine-tuner for target transcripts as discussed by the authors.
Journal ArticleDOI
Novel insights into m6A modification of coding and non-coding RNAs in tumor biology: From molecular mechanisms to therapeutic significance
Jinling Jia,Su-Yao Wu,Zimo Jia,Chang Wang,Chenxi Ju,Jinxiu Sheng,Fucheng He,Mingxia Zhou,Jing He +8 more
TL;DR: Current advances in m 6A modification and the regulatory mechanisms underlying mRNAs and ncRNAs in distinct cancer stages are highlighted and the therapeutic significance of m6A regulators in clinical cancer treatment is focused on.
References
More filters
Journal ArticleDOI
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma
Tony Gutschner,Monika Hämmerle,Nikolaos Pazaitis,Nadine Bley,Evgenij Fiskin,Hannah Uckelmann,Andreas Heim,Matthias Groβ,Nina Hofmann,Robert Geffers,Britta Skawran,Thomas Longerich,Kai Breuhahn,Peter Schirmacher,Britta Mühleck,Stefan Hüttelmaier,Sven Diederichs +16 more
TL;DR: The RNA‐binding protein IGF2 BP1 is an important protumorigenic factor in liver carcinogenesis and therapeutic targeting of IGF2BP1 may offer options for intervention in human HCC.
Journal ArticleDOI
PARP Inhibitors in Ovarian Cancer
Gloria Mittica,Eleonora Ghisoni,Gaia Giannone,Sofia Genta,Massimo Aglietta,Anna Sapino,Giorgio Valabrega +6 more
TL;DR: ParPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease, and further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.
Journal ArticleDOI
Let‐7 modulates acquired resistance of ovarian cancer to Taxanes via IMP‐1‐mediated stabilization of multidrug resistance 1
Benjamin Boyerinas,Sun Mi Park,Andrea E. Murmann,Katja Gwin,Anton G. Montag,Marion Zillhardt,You Jia Hua,Ernst Lengyel,Marcus E. Peter +8 more
TL;DR: Evidence is provided that, although let‐7 is not a universal sensitizer of cancer cells to Taxanes, it affects acquired resistance of cells to this class of drugs by targeting IMP‐1, resulting in destabilization of the mRNA of MDR1.
Journal ArticleDOI
IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling
Nadine Stöhr,Marcel Köhn,Marcell Lederer,Markus Glaß,Claudia Reinke,Robert H. Singer,Stefan Hüttelmaier +6 more
TL;DR: This study reveals that IGF2BP1 promotes the velocity and directionality of tumor-derived cell migration by determining the cytoplasmic fate of two novel target mRNAs: MAPK4 and PTEN.
Journal ArticleDOI
Involvement of Src Family Kinases in N-Cadherin Phosphorylation and β-Catenin Dissociation during Transendothelial Migration of Melanoma Cells
TL;DR: A novel role for tyrosine phosphorylation of N-cadherin by Src family kinases in the regulation of beta-catenin association during transendothelial migration of melanoma cells is suggested.